A Phase 3 study of SAR425899 in Obese/overweight patients with pre-diabetes.
Latest Information Update: 09 Feb 2018
Price :
$35 *
At a glance
- Drugs SAR 425899 (Primary)
- Indications Obesity; Prediabetic state
- Focus Therapeutic Use
- 09 Feb 2018 New trial record
- 07 Feb 2018 According to a Sanofi media release, company is planning to initiate this trial in H2 2018.